/
NRXP
$4.00+$0.27 (+7.24%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$159.6M
43M shares
52-week range
$1.62 – $5.06
69% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
5.17%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-112.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.2M |
| Cost of revenue | $1.0M | $0 | $2.0K | $2.0K | $4.0K | $5.0K | $5.0K | $505.0K |
| Gross profit | −$1.0M | $0 | −$2.0K | −$2.0K | −$4.0K | −$5.0K | −$5.0K | $720.0K |
| Gross margin | — | — | — | — | — | — | — | 58.8% |
| R&D | $0 | $0 | $10.6M | $20.3M | $17.0M | $13.4M | $6.2M | $3.8M |
| Operating income | −$1.0M | −$713.2K | −$22.1M | −$95.2M | −$44.3M | −$27.6M | −$19.7M | −$16.2M |
| EBITDA | $82.4K | $492.6K | −$51.7M | −$93.0M | −$39.8M | −$30.0M | −$24.0M | −$27.8M |
| Net income | $66.1K | $408.4K | −$51.8M | −$93.1M | −$39.8M | −$30.1M | −$25.1M | −$28.6M |
| Net margin | — | — | — | — | — | — | — | -2336.5% |
| EPS (diluted) | 0.07 | 0.80 | -1.51 | -7.44 | -0.60 | -3.98 | -2.39 | -1.34 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14M | $-0.37 | $-0.45–$-0.29 | 2 |
| 2027 | $166M | $0.35 | $0.30–$0.40 | 2 |
| 2028 | $499M | $2.49 | $0.26–$5.76 | 1 |
| 2029 | $745M | $4.51 | $0.48–$10.43 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.72
Price
$4.00
Implied downside
-82%
Peer comparison
NRX Pharmaceuticals, Inc. Common Stock
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
nrxpharma.com- Employees
- 29
- IPO / List date
- May 25, 2021
- HQ
- WILMINGTON, DE
Held by traders on TradeandTell
No one on the platform currently holds NRXP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 128,175 | $423.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-04-02 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded NRXP yet.
